Attenuation of Colon Carcinoma Tumor Spread by Intravenous Immunoglobulin

Authors

  • MAYA DAMIANOVICH,

    1. Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel
    Search for more papers by this author
    • *

      Authors all made equal contributions to the paper.

  • ARIEH SORIN SOLOMON,

    1. Goldschleger Eye Research Institute, Sackler Faculty of Medicine, Tel-Aviv University, Israel
    Search for more papers by this author
    • *

      Authors all made equal contributions to the paper.

  • MIRI BLANK,

    1. Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel
    Search for more papers by this author
  • YEHUDA SHOENFELD

    1. Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel
    2. Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University, Israel
    Search for more papers by this author

Address for correspondence: Y. Shoenfeld, M.D., F.R.C.P., Department of Medicine “B,” The Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, 52621 Israel. Voice: 972-3-5302652; fax: 972-3-5352855.
 shoenfel@post.tau.ac.il

Abstract

Abstract: The impact of IVIg on metastatic capacity of CT26 murine colon carcinoma cells was studied using in vitro and in vivo methods. IVIg inhibited CT26 cell proliferation and invasion through an extracellular matrix in a dose- and time-dependent manner. Systemic treatment of mice with IVIg significantly inhibited metastatic potential of CT26 colon carcinoma cells observed as tumor nodules and lung weight reduction. Treating CT26 cell-implanted rabbit corneas with IVIg led to shrinking and complete disappearance of tumor mass in 10 days. These results provide the evidence that IVIg may be considered as a supportive therapy for inhibition of colon carcinoma tumor spread.

Ancillary